Alvotech(US:ALVO)2025-03-27 13:07Financial Performance & Outlook - Total revenues reached $492 million, exceeding the latest guidance, compared to $93 million in 2023, a 427% increase[25,59] - Product revenues were $273 million, surpassing $49 million in 2023, a 462% increase[25,59] - Adjusted EBITDA was $108 million, a significant turnaround from a loss of $291 million in 2023[25,59] - The company anticipates revenues between $570 million and $670 million in 2025, with product revenue contributing $340 million to $410 million and milestone revenues between $230 million and $260 million[67] - The company projects an adjusted EBITDA between $180 million and $260 million in 2025[67] - Alvotech targets approximately $1.5 billion in revenue by 2028[70,77] - Alvotech targets an EBITDA margin of 40-45% by 2028[73,77] Commercial & R&D Updates - SIMLANDI units shipped to the US across both branded and private label channels in 2024 reached 1.3 million, with 60% of those units shipped in Q4 2024[35] - The company has biosimilar approval in 63 markets and has launched in 29 markets[37] - By the end of 2025, investments will enable a total annual capacity of 15 million finished units[42]